352 related articles for article (PubMed ID: 36896445)
1. Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.
Li X; Sun X; Wang B; Li Y; Tong J
Asian J Pharm Sci; 2023 Jan; 18(1):100771. PubMed ID: 36896445
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Yamada T; Hamano Y; Hasegawa N; Seo E; Fukuda K; Yokoyama KK; Hyodo I; Abei M
Curr Cancer Drug Targets; 2018; 18(2):188-201. PubMed ID: 28359239
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
Moehler M; Heo J; Lee HC; Tak WY; Chao Y; Paik SW; Yim HJ; Byun KS; Baron A; Ungerechts G; Jonker D; Ruo L; Cho M; Kaubisch A; Wege H; Merle P; Ebert O; Habersetzer F; Blanc JF; Rosmorduc O; Lencioni R; Patt R; Leen AM; Foerster F; Homerin M; Stojkowitz N; Lusky M; Limacher JM; Hennequi M; Gaspar N; McFadden B; De Silva N; Shen D; Pelusio A; Kirn DH; Breitbach CJ; Burke JM
Oncoimmunology; 2019; 8(8):1615817. PubMed ID: 31413923
[TBL] [Abstract][Full Text] [Related]
5. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
[TBL] [Abstract][Full Text] [Related]
6. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
8. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.
Jebar AH; Errington-Mais F; Vile RG; Selby PJ; Melcher AA; Griffin S
J Gen Virol; 2015 Jul; 96(Pt 7):1533-50. PubMed ID: 25711964
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
Zheng M; Huang J; Tong A; Yang H
Mol Ther Oncolytics; 2019 Dec; 15():234-247. PubMed ID: 31872046
[TBL] [Abstract][Full Text] [Related]
10. PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Galle PR; Chao Y; Erinjeri J; Heo J; Borad MJ; Luca A; Burke J; Pelusio A; Agathon D; Lusky M; Breitbach C; Qin S; Gane E
Liver Cancer; 2024 Jun; 13(3):248-264. PubMed ID: 38756145
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson A; West EJ; Carmichael J; Scott KJ; Turnbull S; Kuszlewicz B; Dave RV; Peckham-Cooper A; Tidswell E; Kingston J; Johnpulle M; da Silva B; Jennings VA; Bendjama K; Stojkowitz N; Lusky M; Prasad KR; Toogood GJ; Auer R; Bell J; Twelves CJ; Harrington KJ; Vile RG; Pandha H; Errington-Mais F; Ralph C; Newton DJ; Anthoney A; Melcher AA; Collinson F
Cancer Immunol Res; 2022 Jun; 10(6):745-756. PubMed ID: 35439304
[TBL] [Abstract][Full Text] [Related]
12. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
13. Current landscape and perspective of oncolytic viruses and their combination therapies.
Su Y; Su C; Qin L
Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
[TBL] [Abstract][Full Text] [Related]
14. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
15. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C; Xiao G; Wang T; Song L; Peng B; Xu B; Zhang K
Research (Wash D C); 2023; 6():0108. PubMed ID: 37040283
[TBL] [Abstract][Full Text] [Related]
16. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
17. Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy.
Bressy C; Hastie E; Grdzelishvili VZ
Mol Ther Oncolytics; 2017 Jun; 5():20-40. PubMed ID: 28480326
[TBL] [Abstract][Full Text] [Related]
18. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
19. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
20. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
